Omada's presentations at ObesityWeek 2026 highlight successful meal tracking and medication adherence for weight loss programs.
Quiver AI Summary
Omada Health announced two important presentations at ObesityWeek 2026 in Washington, D.C., highlighting their AI-powered Meal Map tool and the success of their GLP-1 Care Track program. The Meal Map tool, designed to improve meal tracking habits by focusing on nutrient quality rather than restrictive diets, showed that participants who used it lost more weight over 16 weeks compared to those who did not. In addition, the GLP-1 Care Track program demonstrated high medication persistence, with 71% of members maintaining their medication for a full year, resulting in an average weight loss of 18.4%, similar to outcomes seen in clinical trials. Omada’s approach emphasizes continuous support between doctor visits, helping members manage emotional eating and adhere to their treatment plans effectively.
Potential Positives
- Omada's AI-powered Meal Map tool demonstrates effectiveness in improving meal tracking habits, with members who used it losing more weight compared to the control group.
- 71% of members on the GLP-1 Care Track maintained their medication for a full year, resulting in significant weight loss comparable to clinical trial outcomes.
- The research presented at ObesityWeek 2026 reinforces Omada's role as an innovative leader in virtual healthcare for obesity management, enhancing its visibility in the sector.
Potential Negatives
- Despite reporting a significant percentage of members staying on GLP-1 medication, the reliance on medication raises concerns about the sustainability of weight loss since it suggests that ongoing pharmacological intervention is necessary for maintaining results.
- The results show that while engagement with support programs leads to better outcomes, it indicates that many users may struggle to achieve desired results without consistent management, which could reflect inadequacies in the program efficacy for some members.
- The focus on a virtual-first model may alienate potential clients who prefer in-person healthcare support, limiting market reach and patient satisfaction among those who value traditional healthcare interactions.
FAQ
What is Omada’s Meal Map tool?
Omada’s Meal Map is an AI-powered tool that helps members track meals by focusing on nutrient quality rather than restricting food choices.
How effective is the GLP-1 Care Track program?
71% of GLP-1 Care Track members remained on their medication for a full year, resulting in an average weight loss of 18.4%.
What are the benefits of using the Meal Map tool?
Members using Meal Map were more likely to track multiple meals and experienced greater weight loss compared to those who didn't.
Who presented Omada’s findings at ObesityWeek 2026?
Alison Megliola, MS, RD, CDCES, and Susan M. Devaraj, PhD, MS, RD, presented the findings on Meal Map and GLP-1 Care Track respectively.
What chronic conditions does Omada Health address?
Omada Health provides support for chronic conditions such as obesity, diabetes, hypertension, and cholesterol through a virtual care model.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OMDA Insider Trading Activity
$OMDA insiders have traded $OMDA stock on the open market 52 times in the past 6 months. Of those trades, 0 have been purchases and 52 have been sales.
Here’s a breakdown of recent trading of $OMDA stock by insiders over the last 6 months:
- SEAN P. DUFFY (Chief Executive Officer) has made 0 purchases and 20 sales selling 159,352 shares for an estimated $3,404,945.
- STEVEN L. COOK (Chief Financial Officer) has made 0 purchases and 18 sales selling 157,200 shares for an estimated $3,382,147.
- WEI-LI SHAO (President) has made 0 purchases and 4 sales selling 17,491 shares for an estimated $389,121.
- CRAIG GRACEY (Chief Accounting Officer) has made 0 purchases and 10 sales selling 18,996 shares for an estimated $371,231.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$OMDA Revenue
$OMDA had revenues of $91.3M in Q3 2026.
You can track OMDA financials on Quiver Quantitative's OMDA stock page.
You can access data on OMDA stock through the Quiver Quantitative API.
$OMDA Hedge Fund Activity
We have seen 132 institutional investors add shares of $OMDA stock to their portfolio, and 60 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- REVELATION CAPITAL MANAGEMENT, LLC removed 4,858,034 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $101,095,687
- NVP ASSOCIATES, LLC removed 2,531,000 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $52,670,110
- DIVISADERO STREET CAPITAL MANAGEMENT, LP removed 2,088,020 shares (-35.5%) from their portfolio in Q2 2026, for an estimated $45,832,039
- BLACKROCK, INC. added 1,538,951 shares (+69.3%) to their portfolio in Q3 2026, for an estimated $32,025,570
- D. E. SHAW & CO., INC. added 1,202,058 shares (+inf%) to their portfolio in Q2 2026, for an estimated $26,385,173
- A16Z CAPITAL MANAGEMENT, L.L.C. removed 1,153,645 shares (-50.0%) from their portfolio in Q2 2026, for an estimated $25,322,507
- QUBE RESEARCH & TECHNOLOGIES LTD added 1,071,608 shares (+1897.9%) to their portfolio in Q3 2026, for an estimated $22,300,162
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$OMDA Analyst Ratings
Wall Street analysts have issued reports on $OMDA in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 11/06/2026
- Freedom Capital Markets issued a "Buy" rating on 10/14/2026
- Needham issued a "Buy" rating on 09/11/2026
- BTIG issued a "Buy" rating on 09/11/2026
- JP Morgan issued a "Overweight" rating on 08/14/2026
- Citizens issued a "Market Outperform" rating on 08/14/2026
- Canaccord Genuity issued a "Buy" rating on 07/21/2026
To track analyst ratings and price targets for $OMDA, check out Quiver Quantitative's $OMDA forecast page.
$OMDA Price Targets
Multiple analysts have issued price targets for $OMDA recently. We have seen 10 analysts offer price targets for $OMDA in the last 6 months, with a median target of $29.0.
Here are some recent targets:
- Saket Kalia from Barclays set a target price of $22.0 on 11/06/2026
- Stan Berenshteyn from Wells Fargo set a target price of $19.0 on 11/06/2026
- Gene Mannheimer from Freedom Capital Markets set a target price of $35.0 on 10/14/2026
- Ryan MacDonald from Needham set a target price of $28.0 on 09/11/2026
- David Larsen from BTIG set a target price of $35.0 on 09/11/2026
- Constantine Davides from Citizens set a target price of $32.0 on 08/14/2026
- Lisa Gill from JP Morgan set a target price of $30.0 on 08/14/2026
Full Release
Omada’s AI-powered Meal Map tool, built to focus on nutrient quality rather than restrictive eating, helped members build meal-tracking habits linked to greater weight loss at week 16.
In Omada’s GLP-1 Care Track, 71% of members stayed on their medication for a full year, and those who did lost 18.4% of body weight, comparable to clinical trials.
SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, announced two presentations at ObesityWeek 2026, taking place November 14-17, 2026, in Washington, D.C. The research looks at the support people need between doctor visits, including building food habits that fit daily life and staying on GLP-1 treatment for a full year to get the most out of the medication.
Poster Presentation #308: AI-Powered Meal Feedback Is Linked to More Meal Tracking and Greater Weight Loss in a Virtual Lifestyle Program
The first presentation highlights how Omada’s AI-powered tool, Meal Map, may help people who struggle with emotional eating and cravings build tracking habits that support weight loss. 1 Meal Map, now available in Omada’s cardiometabolic programs, provides members with real-time, AI-powered feedback on every meal logged, focusing on nutrient quality rather than restrictive eating. Instead of scoring foods as “good” or “bad,” AI technology identifies the nutrient-dense parts of a meal and the gaps in its balance alongside actionable guidance for future meals.
In this analysis, 13,852 members who joined Omada’s behavior change program between September and November 2025 and reported emotional eating, trouble managing cravings or snacking often were randomized into two groups. The control group received Omada’s core nutrition features, including meal tracking, care team alerts when nutrition patterns changed, and the OmadaSpark chatbot, an AI-powered resource for nutrition education. The second group received those same features plus Meal Map. 1
Compared with the control group, Meal Map members 1 :
- Were more likely to track at least three meals in their first month (41.1% vs. 36.0%).
- Had 34% greater odds of tracking at least three meals every month through 16 weeks.
-
Lost more weight at week 16 if they tracked at least three meals in their first month (3.47% vs. 3.02%).
Alison Megliola, MS, RD, CDCES, Director of Clinical Product, presented the poster on Saturday, November 14, 2026, from 7:30 to 8:30 PM ET at ObesityWeek 2026.
Poster Presentation #533: Virtual Lifestyle Program Support for GLP-1 Therapy: 12-Month Persistence and Weight Outcomes in Adults With Obesity
The second presentation builds on 12-month GLP-1 Care Track results Omada shared in January 2026. 2 The analysis included 969 adults without diabetes who started a GLP-1 between 60 days before and 30 days after enrolling in Omada’s GLP-1 Care Track between June and September 2024. Medication persistence was confirmed through pharmacy claims. 3
Key findings include 3 :
- 71% stayed on GLP-1 medication at 52 weeks after their first fill.
- Members who stayed on medication the full year lost an average of 18.4% of body weight, comparable to clinical trial outcomes (approximately 16-17% with semaglutide and approximately 20% with tirzepatide), 4,5 and the full cohort lost an average of 16.3% of body weight at 12 months regardless of time on medication.
- Each additional five weekly engagement actions was associated with 28% greater adjusted odds of staying on medication and, among those who stayed on, 28% greater odds of reaching 15% weight loss.
-
Among members who stopped medication, early findings suggested potential for weight maintenance after discontinuation.
Omada’s GLP-1 Care Track supports members taking GLP-1s between doctor visits, and if they stop, helps with the transition off medication. Each member works with a dedicated care team to receive ongoing support on side effects, medication questions and GLP-1-specific nutrition, along with access to GLP-1 peer communities and digital tools for meal logging, behavior tracking and nutrition. Members also have access to an exercise specialist and customized plans to maintain lean mass. In this analysis, members who engaged with Omada’s support more often were more likely to stay on their medication.
“Patients often leave a doctor’s visit with good advice about how to eat, and then they have to make it work on their own until the next appointment,” said Thomas Tsang, MD, MPH, Chief Medical Officer at Omada Health. “That’s harder for people who deal with emotional eating or cravings, because those moments rarely happen in the exam room. Feedback right after a meal is logged gives them support when they need it. Across both analyses, members who stayed engaged between visits did better, whether that meant building a tracking habit or staying on a GLP-1 for a full year.”
The GLP-1 Care Track analysis was completed as part of the Omada Insights Lab ANSWERS (ANalyzing Success of WEight medication with Real-world evidence and Stats) Initiative, which examines and shares real-world data from Omada’s behavior change weight health programs.
Omada Health’s Senior Clinical Research Scientist, Susan M. Devaraj, PhD, MS, RD, presented the analysis on Sunday, November 15, 2026, from 2:30 to 3:30 PM ET at ObesityWeek 2026.
Omada Health
Omada Health (Nasdaq: OMDA) is reverse engineering the way healthcare is delivered in America, putting the space between doctor visits–where health is won or lost–at the center of care. Today’s healthcare system poorly serves chronic conditions that require ongoing support outside of the exam room, like obesity, diabetes, hypertension, cholesterol, and musculoskeletal conditions. Omada’s virtual-first model combines human-led care teams, connected devices, and AI-enabled technology to deliver personalized care at scale, including support for GLP-1 therapy. Omada has served more than two million members since launch across 2,000+ employers, health plans, pharmacy benefit managers, and health systems. Learn more at
omadahealth.com
.
Media Contact
Rose Ramseth
[email protected]
References
- Naqvi JB, Stanton LA, Linesch S, et al. AI-powered meal feedback is linked to more meal tracking and greater weight loss in a virtual lifestyle program. Poster presented at: ObesityWeek 2026; November 14-17, 2026; Washington, D.C.
- Omada Health. Omada Health's GLP-1 behavior change companion programs help drive lasting, long-term weight loss. News release. Published January 8, 2026. Accessed November 14, 2026. https://www.omadahealth.com/resource-center/omada-healths-glp-1-behavior-change-companion-programs-help-drive-lasting-long-term-weight-loss
- Devaraj SM, Napoleone J, Naqvi JB, Chang H, Linke S. Virtual lifestyle program support for GLP-1 therapy: 12-month persistence and weight outcomes in adults with obesity. Poster presented at: ObesityWeek 2026; November 15, 2026; Washington, D.C.
- Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med . 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
-
Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity.
N Engl J Med
. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038